All news

© GettyImages/AndreyPopov

Disruptor in cell and gene therapy space secures US$30m in funding

By Jane Byrne

Ori Biotech Ltd (Ori), a London and New Jersey based innovator in the cell and gene therapy (CGT) manufacturing sphere, last week announced the successful close of a US$30m Series A financing round, bringing the company’s total funding to date to US$41m.

Follow us

Products

View more

Webinars